Actively Recruiting
CAYA Cancer Retrospective Cohort Study
Led by Resonance, Inc. · Updated on 2025-12-19
18000
Participants Needed
5
Research Sites
182 weeks
Total Duration
On this page
Sponsors
R
Resonance, Inc.
Lead Sponsor
S
Servier Affaires Médicales
Collaborating Sponsor
AI-Summary
What this Trial Is About
Despite advances in cancer treatment, significant disparities in outcomes persist between high-income countries (HICs) and low-and middle-income countries (LMICs). Around 80% of children with cancer live in LMICs, where they face challenges such as delayed diagnosis, misdiagnosis, comorbidities, distance to treatment, financial barriers, and limited access to risk-adapted therapies. Acute lymphoblastic leukemia(ALL)/lymphoblastic lymphoma(LBL), for example, is one of the greatest success stories in pediatric oncology, however, such improvements are not evenly distributed worldwide, and the outcomes for leukemia patients are poorer in LMICs compared to HICs, primarily due to reduced access to quality healthcare. This study aims to assess cancer treatment outcomes in LMICs, focusing on acute lymphoblastic leukemia/lymphoblastic lymphoma. The findings will inform future studies to implement evidence-based interventions that improve care quality and reduce treatment failures through targeted strategies.
CONDITIONS
Official Title
CAYA Cancer Retrospective Cohort Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be willing and able to provide informed consent before enrollment, or assent with guardian consent for minors or those unable to consent.
- Diagnosed with any type of cancer within 15 years prior to the site's activation date.
- Aged from 0 to 21 years at the time of diagnosis.
- Received substantial anti-cancer treatment at the participating center, including chemotherapy, surgery, radiation therapy, or immunotherapy.
- Medical records must be available and accessible for review.
You will not qualify if you...
- Patients who only visited the participating center for consultation without receiving primary anti-cancer treatment there.
- Patients who only had pathology, radiology, or other diagnostic evaluations without treatment at the participating center.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Yeolyan Center for Cancer and Blood Disorders
Yerevan, Armenia
Actively Recruiting
2
Fundación Ayúdame a Vivir
El Salvador, El Salvador, El Salvador, 1101
Not Yet Recruiting
3
Unidad Nacional de Oncología Pediátrica (UNOP)
Guatemala City, Guatemala
Actively Recruiting
4
Hospital Mario Catarino Rivas
San Pedro Sula, Cortés Department, Honduras, 21102
Not Yet Recruiting
5
Hospital Escuela
Tegucigalpa, Distrito Central, Honduras, 11101
Not Yet Recruiting
Research Team
G
Gabriela Villanueva, MD.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here